NovaBay Pharma Files Proxy Solicitation Material
Ticker: NBY · Form: DEFA14A · Filed: Mar 7, 2025 · CIK: 1389545
Sentiment: neutral
Topics: proxy-solicitation, shareholder-communication, regulatory-filing
Related Tickers: NBY
TL;DR
NovaBay Pharma is sending out proxy materials, get ready for a shareholder vote.
AI Summary
NovaBay Pharmaceuticals, Inc. filed a DEFA14A on March 7, 2025, related to a previous 8-K filing from March 4, 2025. This filing is soliciting material under Rule 14a-12 of the Exchange Act, indicating it's related to proxy solicitations or shareholder communications.
Why It Matters
This filing indicates NovaBay Pharmaceuticals is engaging in shareholder communications, potentially related to upcoming votes or proposals that could impact the company's direction.
Risk Assessment
Risk Level: medium — DEFA14A filings often precede significant corporate actions or shareholder votes, which can introduce uncertainty and potential volatility.
Key Numbers
- 001-33678 — SEC File Number (NovaBay Pharmaceuticals' SEC file number)
- 68-0454536 — IRS Number (NovaBay Pharmaceuticals' IRS Employer Identification Number)
Key Players & Entities
- NovaBay Pharmaceuticals, Inc. (company) — Filer of the DEFA14A and 8-K
- 0001437749-25-006556 (filing_id) — Accession Number for the DEFA14A filing
- March 7, 2025 (date) — Filing date of the DEFA14A
- March 4, 2025 (date) — Date of the earliest event reported in the 8-K
- Rule 14a-12 (regulation) — Rule under which soliciting material is filed
FAQ
What is the primary purpose of this DEFA14A filing?
The DEFA14A filing is intended to simultaneously satisfy the filing obligation of the registrant under Rule 14a-12 of the Exchange Act, indicating it is soliciting material.
What is the earliest event date mentioned in the related 8-K filing?
The earliest event reported in the related 8-K filing is March 4, 2025.
When was this DEFA14A filing submitted to the SEC?
This DEFA14A filing was submitted on March 7, 2025.
What is NovaBay Pharmaceuticals' principal executive office address?
NovaBay Pharmaceuticals' principal executive office is located at 2000 Powell Street, Suite 1150, Emeryville, CA 94608.
Under which act is this DEFA14A filing made?
This DEFA14A filing is made pursuant to the Securities Exchange Act of 1934.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on March 7, 2025 regarding NovaBay Pharmaceuticals, Inc. (NBY).